Seaport Therapeutics Prices Upsized IPO at $18 Per Share

Seaport Therapeutics Announces $254.9 Million Upsized IPO

Seaport Therapeutics Inc., a clinical-stage biopharmaceutical company, announced the pricing of its upsized initial public offering. The company will issue 14,160,000 shares of common stock at a public offering price of $18.00 per share, which was at the high end of its target range.

The offering is expected to generate gross proceeds of approximately $254.9 million, before deducting underwriting discounts and commissions.

Overview of the Offering

Seaport Therapeutics focuses on developing novel treatments for neuropsychiatric disorders such as depression and anxiety. The company utilizes its proprietary Glyph platform to create oral therapies designed to overcome limitations of existing treatments.

The shares are scheduled to begin trading on the Nasdaq Global Select Market on May 1, 2026, under the ticker symbol SPTX. The offering's closure is anticipated on May 4, 2026, subject to standard closing conditions.

Market and Financial Impact

The successful pricing at the top of the expected range indicates strong investor demand for Seaport's specialized approach to neuropsychiatric medicine. The capital raised will be critical for advancing the company's clinical pipeline and funding further research and development.

Underwriters, including Goldman Sachs & Co. LLC and J.P. Morgan, have a 30-day option to purchase up to an additional 2,124,000 shares at the IPO price.

Summary

This upsized IPO marks a significant milestone for Seaport Therapeutics, providing substantial funding to pursue its mission of developing new medicines. The market's reception to the SPTX stock debut will be a key indicator of investor confidence in the biotechnology sector and the company's long-term potential.

FAQ

Q: What is Seaport Therapeutics' IPO price?
A: The initial public offering was priced at $18.00 per share.

Q: How much capital did Seaport Therapeutics raise in its IPO?
A: The company expects to receive gross proceeds of $254.9 million before offering expenses.

Q: What is the ticker symbol for Seaport Therapeutics?
A: The company will trade on the Nasdaq under the ticker symbol SPTX.

Source: Investing.com